KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Current Leases (2019 - 2025)

Twist Bioscience (TWST) has disclosed Current Leases for 5 consecutive years, with $13.4 million as the latest value for Q1 2023.

  • On a quarterly basis, Current Leases fell 5.44% to $13.4 million in Q1 2023 year-over-year; TTM through Mar 2023 was $13.4 million, a 5.44% decrease, with the full-year FY2022 number at $13.6 million, up 66.1% from a year prior.
  • Current Leases was $13.4 million for Q1 2023 at Twist Bioscience, down from $13.6 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $14.2 million in Q1 2022 to a low of $6.4 million in Q3 2020.
  • A 5-year average of $9.6 million and a median of $8.2 million in 2021 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: fell 16.24% in 2021, then skyrocketed 117.47% in 2022.
  • Twist Bioscience's Current Leases stood at $8.4 million in 2019, then fell by 23.44% to $6.4 million in 2020, then surged by 97.91% to $12.7 million in 2021, then rose by 7.55% to $13.6 million in 2022, then fell by 1.8% to $13.4 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Current Leases are $13.4 million (Q1 2023), $13.6 million (Q3 2022), and $14.2 million (Q1 2022).